The REVIVED study aimed to assess whether the addition of stents when treating patients with severe ischaemic cardiomyopathy would be beneficial to patient outcomes. In this touchCARDIO interview, we speak with Professor Divaka Perera (King’s College London, London, UK) to discuss the REVIVED trial, its outcomes and how they will affect the current treatment paradigm.
The abstract entitled ‘REVIVED – Percutaneous Revascularisation for Ischaemic Ventricular Dysfunction’ was presented at the European Society of Cardiology (ESC) Congress 2022, 26 – 29 August 2022.
Questions:
- What were the aims, design and eligibility criteria of the REVIVED clinical study? (0:18)
- What were the efficacy and safety findings in the two study arms? (3:50)
- What are the implications of these findings for the future place of PCI in the treatment paradigm for heart failure? (6:42)
Disclosures: Divaka Perera has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Danielle Crosby.
Filmed as a highlight of ESC 2022
Access more content on Heart Failure here and Cardiovascular Disease here
